ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease
13 April 2023 - 11:07PM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of inflammatory and renal diseases, announces
publication of a review article in Frontiers in Pharmacology
addressing the NLRP3 inflammasome pathway as a potential drug
target for treating mild cognitive impairment (“MCI”) and AD.
In the paper titled, “Microglia: A pharmacological target for
the treatment of age-related cognitive decline and Alzheimer’s
disease,” the authors reviewed data associated with microglial
pathways that have potential as drug targets for treatment of MCI
and AD. Reported data supporting the NLRP3 inflammasome pathway as
a drug target are summarized below:
- IL-1β, which is considered toxic to
microglia by triggering increased oxidative stress and apoptosis
(“cell death”), is elevated in cerebrospinal fluid and brains of
patients with AD
- IC 100, an anti-ASC antibody which
permeates the blood-brain-barrier and binds to ASC filaments,
blocks IL-1β production in human whole blood cell assays
- Inflammasome ASC, which is produced
by microglia, binds to amyloid beta (“Aβ”) and aids in formation of
Aβ oligomers - administration of an anti-ASC antibody in an AD
mouse model prevented Aβ from accumulating
- AD mouse models deficient in NLRP3
or caspase-1 demonstrate reduced activation of IL-1β and reduced
spatial memory loss
- Administration of a caspase-1
inhibitor in a mouse model of “Aβ” pathology reversed impairment of
episodic and spatial memory, while preventing brain inflammation
and Aβ build up
- Administration of a compound that
inhibits NLRP3 assembly, reduced levels of IL-1β and Aβ which were
associated with improved working and recognition memory in an AD
mouse model; this compound administered to a Tau-P301S mouse model
of AD prevented Tau pathology
The authors stated, “thus far, animal models testing NLRP3
pathway inhibitors suggest that such treatments may have
pharmacologic relevance in reducing cognitive aging and AD
pathology within patients.” To read the article Click Here.
“There is a tremendous unmet need to identify effective
therapies to treat the growing number of people with cognitive
impairment and Alzheimer’s disease, a leading cause of disability
and death in the world,” stated Stephen C. Glover, ZyVersa’s
Co-founder, Chairman, CEO, and President. “It is encouraging to see
the extensive research underway to identify potential drug targets.
We are proud of the original scientific contributions in this area
by the inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100,
Drs. Robert W. Keane and Juan Pablo de Rivero Vaccari at the
University of Miami Miller School of Medicine.” To review their
latest publication on Alzheimer’s disease, Click Here.
About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that
inhibits the inflammasome adaptor protein ASC. IC 100 was designed
to attenuate both initiation and perpetuation of the inflammatory
response. It does so by binding to a specific region of the ASC
component of multiple types of inflammasomes, including (NLRP1,
NLRP2, NLRP3, NLRC4, AIM2, Pyrin). Intracellularly, IC 100 binds to
ASC monomers, inhibiting inflammasome formation, thereby blocking
activation of IL-1β early in the inflammatory cascade. IC 100 also
binds to ASC in ASC Specks, both intracellularly and
extracellularly, further blocking activation of IL-1β and the
perpetuation of the inflammatory response that is pathogenic in
inflammatory diseases. Because active cytokines amplify adaptive
immunity through various mechanisms, IC 100, by attenuating
cytokine activation, also attenuates the adaptive immune
response.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment
of kidney diseases, and Inflammasome ASC Inhibitor IC 100,
targeting damaging inflammation associated with numerous CNS and
other inflammatory diseases. For more information, please visit
www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate and IR Contact:Karen CashmereChief
Commercial Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic
Advisors, Inc.Casey
McDonaldcmcdonald@tiberend.com646-577-8520
Dave Schemeliadschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Feb 2024 to Mar 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Mar 2023 to Mar 2024